Cristin Hubbard
Known title: EVP, Chief Commercial OfficerCIK: 0002021836
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 2,318 | $116K | 5/20/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,245 | $70K | 3/17/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 15,410 | $0 | 3/16/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 2,155 | $129K | 5/20/2025 | View on chart |
| BMRN | ▼ Sell | Open Market | 273 | $18K | 5/2/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 273 | $15K | 4/30/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 13,310 | $0 | 3/17/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 14,690 | $0 | 5/20/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,700 | $0 | 5/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.